Anifrolumab for Cutaneous Lupus
Quick Facts
What Did the Anifrolumab Skin Lupus Study Find?
The investigator-initiated study focused on chronic cutaneous lupus erythematosus, an autoimmune disease in which persistent inflammation can produce painful or disfiguring skin lesions, pigment changes and permanent scarring. According to the initial report, patients treated with anifrolumab experienced favorable infection and hospitalization outcomes, although complete peer-reviewed data are needed to assess the size, reliability and clinical relevance of the association.
A single-site study cannot by itself show that anifrolumab caused the reported outcomes. Patient selection, disease severity, other medicines and differences in medical follow-up may influence infection and hospitalization rates. Larger multicenter studies with appropriate comparison groups will be important before the findings can support broad changes in cutaneous-lupus care.
How Does Anifrolumab Work in Lupus?
Anifrolumab is a monoclonal antibody that binds subunit 1 of the type I interferon receptor, known as IFNAR1. This suppresses signaling from several type I interferons involved in lupus inflammation. The pivotal TULIP-2 trial, published in The New England Journal of Medicine, demonstrated improvement in a composite measure of systemic lupus activity and contributed to the drug's regulatory development.
The U.S. Food and Drug Administration approved anifrolumab, marketed as Saphnelo, for adults with moderate-to-severe systemic lupus erythematosus who are receiving standard therapy. Its effects on lupus-related skin disease are biologically plausible, but use specifically for isolated chronic cutaneous lupus requires individualized specialist assessment because that population is not identical to the systemic-lupus trial population.
What Safety Questions Remain for Patients?
Anifrolumab changes immune signaling and is not free of infection risk. FDA prescribing information warns about serious infections and notes an increased occurrence of respiratory infections and herpes zoster in clinical trials. Patients should be evaluated for infection before treatment and should promptly report fever, new breathing symptoms, a painful blistering rash or other signs of illness.
Clinicians must also consider hypersensitivity and infusion-related reactions, vaccination status, pregnancy considerations and concurrent immunosuppressive therapy. Live vaccines should generally be avoided during treatment. For patients with skin-predominant lupus, any potential benefit must be weighed against established options such as sun protection, topical medicines, antimalarial therapy and other systemic treatments selected by a dermatologist or rheumatologist.
Frequently Asked Questions
In the United States, anifrolumab is approved for adults with moderate-to-severe systemic lupus erythematosus receiving standard therapy. It does not have a separate FDA indication for isolated chronic cutaneous lupus, so treatment decisions require specialist evaluation.
No. The reported findings are preliminary and come from a single site. They show an association that requires confirmation, while FDA prescribing information continues to identify serious infections as a potential treatment risk.
No medication should be stopped without guidance from the prescribing clinician. Anifrolumab is approved for use alongside standard therapy, and changes depend on disease activity, treatment response and safety.
References
- Medical Xpress. Immune drug anifrolumab linked to lower risk of infection and hospitalization for skin lupus. September 2026.
- U.S. Food and Drug Administration. Saphnelo (anifrolumab-fnia) Prescribing Information.
- Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. The New England Journal of Medicine. 2020;382:211-221.